PainChek

PainChek Asset Growth

The Year-over-Year Total Asset Growth of PainChek (PCK.AX) as of Nov 1, 2026 is 254.84 %. In the previous year, Year-over-Year Total Asset Growth was -48.60 % — a change of -624.37% (higher).

Asset Growth

254.84 %

YoY

-624.37%

Last updated:

Year-over-Year Total Asset Growth of PainChek is 2026 254.84 % . Year-over-Year Total Asset Growth of PainChek was 2025 -48.60 % . It decreases by -624.37% higher compared to the previous year.

The PainChek Asset Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Asset Growth
Date
Asset Growth
Jan 1, 2019
29.32 AUD
Jan 1, 2020
30.87 AUD
Jan 1, 2021
90.02 AUD
Jan 1, 2022
-43.68 AUD
Jan 1, 2023
-57.98 AUD
Jan 1, 2024
49.62 AUD
Jan 1, 2025
-48.60 AUD
Jan 1, 2026
254.84 AUD
The PainChek Asset Growth history
YEARAsset GrowthYoY
254.84 %-624.37%
-48.60 %-197.94%
49.62 %-185.58%
-57.98 %+32.75%
-43.68 %-148.52%
90.02 %+191.58%
30.87 %+5.30%
29.32 %-19.76%
36.54 %-98.37%
2,245.38 %-2,461.26%
-95.09 %-166.29%
143.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PainChek Stock analysis

What does PainChek do? PainChek Ltd. develops and commercializes mobile medical device applications, focusing on pain assessment for individuals unable to communicate with carers. The PainChek Universal combines the PainChek Application with the numerical rating scale (NRS), using artificial intelligence and facial recognition to detect pain in non-verbal patients. It provides a point-of-care solution that offers objectivity and consistency in pain assessments, supporting both non-verbal and self-reporting individuals through integrated tools. Healthcare providers and care facilities purchase PainChek Universal to enhance pain management protocols for patients with communication difficulties. The PainChek Application utilizes artificial intelligence and facial recognition technology to assess pain without relying on patient self-reporting, making it suitable for those with cognitive or physical impairments. PainChek Universal integrates the NRS for patients who can self-report, ensuring a comprehensive approach to pain evaluation across varying patient capabilities. This dual functionality allows healthcare professionals to apply consistent assessment standards regardless of a patient's ability to communicate. PainChek Ltd. generates revenue through the commercialization of its mobile medical device applications, specifically targeting healthcare providers and care facilities that require standardized pain assessment tools. The company’s products are designed to address the needs of patients who cannot communicate pain, thereby filling a critical gap in healthcare services. By offering a unified solution that combines AI-driven detection with traditional rating scales, PainChek Universal meets the demands of modern healthcare environments seeking objective and reliable pain management solutions. PainChek is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PainChek stock

Year-over-Year Total Asset Growth of PainChek is 254.84 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Total Asset Growth PainChek since 2006 – with annual values, charts, and detailed analysis.

Asset growth measures the percentage change in total assets. Rapid asset growth may indicate expansion but can also correlate with lower future returns.

To evaluate Year-over-Year Total Asset Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Total Asset Growth.

Year-over-Year Total Asset Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Total Asset Growth's PainChek historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — PainChek

All Key Metrics — PainChek